SCHEMBL5685200

SCHEMBL5685200

CCN(CC)C(=O)CC(c1cccc(F)c1)c1cccc(F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.57
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPT P10636 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
ALDH1A1 P00352 2/20 0.54
PKM P14618 1/20 0.54
TSHR P16473 1/20 0.54
GLA P06280 1/20 0.52
RECQL P46063 1/20 0.52
HCRTR2 O43614 1/20 0.46
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
LTB4R Q15722 1/20 0.45
LTB4R2 Q9NPC1 1/20 0.45
HTT P42858 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5687706 0.84 MEN1 (0.49) MEN1KMT2AOPRM1HDAC4HDAC7
SCHEMBL11385152 0.82 HPGD (0.71) HPGDMEN1KMT2AMAPTNPSR1
SCHEMBL9154048 0.81 HPGD (0.58) HPGDMEN1KMT2AMAPTNPSR1
SCHEMBL5152883 0.79 HDAC4 (0.49) MEN1KMT2AMAPTHDAC4HDAC7
SCHEMBL5685475 0.79 MAPT (0.55) MEN1KMT2AMAPTNPSR1ALDH1A1
SCHEMBL5149908 0.79 HDAC4 (0.51) MEN1KMT2AMAPTHDAC4HDAC7
SCHEMBL27399561 0.77 HPGD (0.54) HPGDMEN1KMT2AMAPTNPSR1
SCHEMBL355557 0.76 OPRM1 (0.46) MEN1KMT2AOPRM1OPRD1HDAC4
SCHEMBL5685868 0.76 CNR2 (0.49) HPGDMAPTOPRM1HDAC4HDAC7
SCHEMBL5514429 0.76 HDAC4 (0.49) MEN1KMT2AMAPTHDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1640359-A2 ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES NPS PHARMACEUTICALS, INC. (US) 2006-03-29 EP claimed
EP-1042275-B1 ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES NPS PHARMA INC (US) 2005-11-09 EP claimed
US-20030199589-A1 Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses NPS PHARMACEUTICALS, INC. 2003-10-23 US claimed
US-7268166-B2 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases NPS PHARMACEUTICALS, INC. (US) 2007-09-11 US disclosed
US-7268166-B2 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases NPS PHARMACEUTICALS, INC. (US) 2007-09-11 US disclosed
EP-1042275-B1 ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES NPS PHARMA INC (US) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199589-A1 Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses GABRE, GABRA2, GABRB2 HPGD 4183/4885MEN1 3260/4885KMT2A 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.